Janssen Pharmaceutica’s parent, Johnson & Johnson is bringing forward the tests because preclinical lab tests were so promising. 1,045 adults aged between 18 and 55 as well as some seniors will test the recombination vaccine Ad26.COV2-6. The vaccine is produced using a special DNA recombination technique. Scientists build several of the virus’s genes in a guest cell.
The genes possess the code of proteins that stimulate your resistance. The guest cells then produce and purify the proteins. The proteins then form the basis for the recombination vaccine that should build up resistance in your body.
The test will involve some volunteers receiving the vaccine and others getting a placebo. Neither the researchers nor the volunteers will initially know who gets what. The test will probe safety, the vaccine’s ability to trigger a reaction and the response of the immune system.
Together with partners Johnson & Johnson is investing in technology and capacity to produce the vaccine on a large scale. It plans to supply a billion vaccines next year.